Fabiana Perna

Hematology

4117 E Fowler Ave
Tampa, FL 33617

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Journal: Blood advances

Published: April 08, 2026

A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

Journal: Bone marrow transplantation

Published: December 18, 2025

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Journal: Bone marrow transplantation

Published: November 07, 2025

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.

Journal: Blood advances

Published: October 30, 2025

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Journal: Blood advances

Published: October 30, 2025

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

Journal: Blood

Published: September 29, 2025

On the Road to Safer CAR Therapy for B-Cell Lymphoma: Real-World Evidence.

On the Road to Safer CAR Therapy for B-Cell Lymphoma: Real-World Evidence.

Journal: Transplantation and cellular therapy

Published: July 05, 2025

Expanded antigen-specific donor regulatory T cells for GVHD prevention.

Expanded antigen-specific donor regulatory T cells for GVHD prevention.

Journal: Blood

Published: July 02, 2025

Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma.

Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma.

Journal: Haematologica

Published: March 12, 2025

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant.

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant.

Journal: American journal of hematology

Published: January 24, 2025

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma.

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 12, 2024

Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma.

Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma.

Journal: Cancer cell

Published: October 31, 2024

Showing 1-12 of 77

Last Updated: 09/26/2026